COVID-19–directed therapies
| . | N (%) . | P value . | |
|---|---|---|---|
| Vaccinated (n = 243) . | Unvaccinated (n = 175) . | ||
| Remdesevir | 60 (25) | 67 (38) | .003 |
| Steroids | |||
| Dexamethasone | 45 (19) | 38 (22) | .42 |
| Methylprednisolone | 25 (10) | 32 (18) | .02 |
| Tocilizumab | 15 (6) | 15 (9) | .35 |
| Anakinra | 0 | 2 (1) | .17 |
| Monoclonal antibodies | 90 (37) | 47 (27) | .04 |
| . | N (%) . | P value . | |
|---|---|---|---|
| Vaccinated (n = 243) . | Unvaccinated (n = 175) . | ||
| Remdesevir | 60 (25) | 67 (38) | .003 |
| Steroids | |||
| Dexamethasone | 45 (19) | 38 (22) | .42 |
| Methylprednisolone | 25 (10) | 32 (18) | .02 |
| Tocilizumab | 15 (6) | 15 (9) | .35 |
| Anakinra | 0 | 2 (1) | .17 |
| Monoclonal antibodies | 90 (37) | 47 (27) | .04 |